Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age

PHASE1CompletedINTERVENTIONAL
Enrollment

394

Participants

Timeline

Start Date

August 15, 2022

Primary Completion Date

October 7, 2022

Study Completion Date

October 7, 2022

Conditions
Pneumococcal Disease
Interventions
OTHER

Candidate-1

Biological

OTHER

Candidate-2

Biological

OTHER

Candidate-3

Biological

OTHER

Candidate-4

Biological

OTHER

Candidate-5

Biological

OTHER

Candidate-6

Biological

OTHER

Candidate Control

Biological

BIOLOGICAL

13vPnC

13-valent pneumococcal conjugate vaccine

BIOLOGICAL

PCV15

15-valent pneumococcal conjugate vaccine

Trial Locations (18)

21075

Centennial Medical Group, Elkridge

23502

Alliance for Multispecialty Research, LLC, Norfolk

28401

Accellacare - Wilmington, Wilmington

33012

Indago Research & Health Center, Inc, Hialeah

33143

Qps-Mra, Llc, South Miami

33308

Proactive Clinical Research,LLC, Fort Lauderdale

48098

Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy

55114

Prism Research LLC dba Nucleus Network, Saint Paul

77375

DM Clinical Research, Tomball

78229

Clinical Trials of Texas, LLC, San Antonio

Diagnostics Research Group, San Antonio

IMA Clinical Research San Antonio, San Antonio

84109

J. Lewis Research, Inc. / Foothill Family Clinic, Salt Lake City

84121

J. Lewis Research, Inc. / Foothill Family Clinic South, Salt Lake City

92780

Orange County Research Center, Tustin

94598

Diablo Clinical Research, Inc., Walnut Creek

06460

Clinical Research Consulting, Milford

08244

South Jersey Infectious Disease, Somers Point

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05489328 - Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age | Biotech Hunter | Biotech Hunter